drugset / Trial / NCT00199212
PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to determine the feasibility of the combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) and to determine the best dose of bortezomib to combine with two trastuzumab schedules, weekly and 3-weekly.
Timeline
- Start
- 2003-10
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |